Today, HepVu launched new interactive maps visualizing state-level estimates of people living with Hepatitis C across the United States that highlight a concentration of infections in some states most impacted by the opioid epidemic. Published in JAMA Network Open, the data reveal an estimated 2.3 million people living with Hepatitis C infection in the US between 2013 and 2016, with a high burden in the West and in some Appalachian states.
The American Gastroenterological Association (AGA) announced 'Inflammatory Bowel Disease (IBD) in Pregnancy Clinical Care Pathway - A Report from the American Gastroenterological Association IBD Parenthood Project Working Group' published online today ahead of print. The new pathway creates a standardized work flow among health care providers (HCPs) who treat women with IBD throughout all stages of family planning.
Lingering inflammation in the colon is a known risk factor for colorectal cancer and now scientists report one way it resets the stage to enable this common and often deadly cancer.
New research from the University of Chicago shows that healthy infants have intestinal bacteria that prevent the development of food allergies.
Most patients with ulcerative colitis (UC) have mild-to-moderate disease characterized by periods of activity or remission, but practice variations exist in disease management. A new clinical guideline from the American Gastroenterological Association (AGA) published in Gastroenterology, the official journal of AGA, addresses the medical management of these patients, focusing on use of both oral and topical 5-aminosalicylates (5-ASA) medications, rectal corticosteroids and oral budesonide, to promote high-quality care for UC patients.
A study published today in the journal Gut shows that women with inflammatory bowel disease (IBD) are at greater risk of developing a mental illness after giving birth compared to the overall population. Study authors found that more than one-fifth of pregnant women with IBD had a new-onset mental health diagnosis. For every 43 pregnancies, there is one extra case of mental illness in a woman with IBD, compared to other women.
The microbial metabolite, Urolithin A, derived from a compound found in berries and pomegranates, can reduce and protect against inflammatory bowel disease (IBD). Urolithin A (UroA) and its synthetic counterpart, UAS03, mitigate IBD by increasing proteins that tighten epithelial cell junctions in the gut and reducing gut inflammation in animal models. Tight junctions in the gut barrier prevent inappropriate microorganisms and toxins from leaking out, causing inflammation characteristic of IBD.
One in six Americans experience constipation, but far fewer want to talk about it. However, avoiding the conversation with your doctor and ignoring issues in the bathroom can not only make you feel bad, but can lead to more serious health issues. Now, a new study finds the solution to these common bowel issues may be as simple as boosting your feet on a stool.
A team of scientists from inStem, Bangalore, and University of Louisville, USA, have ascertained that a microbial metabolite (Urolithin A) derived from berries and pomegranates, and its novel synthetic analog, can mitigate IBD by increasing proteins that tighten epithelial cell junctions in the gut thereby reducing the gut inflammation.
Using a unique bioinformatics technique developed at the University of Alabama at Birmingham, UAB researchers have detected the emergence of new strains of microbes in the human fecal microbiota after obesity surgery. These new strains emerged after surgical disruption of the stomach and upper small intestine. In contrast, the researchers found that strains of the human gut fecal microbiota resembled those found pre-surgery following surgery in the colon.